Poxel appoints Noah Beeman as EVP of business development and president of US operations

21 May 2015

French biopharma company Poxel has appointed Noah Beeman as executive vice president of business development and president of US operation to spearhead the company’s expanding presence in the USA.

He will be based in the Boston area, and will be responsible for leading Poxel’s global business development efforts and building the company’s relationship with the US financial community.

Thomas Kuhn, chief executive of Poxel, said: “Over the course of his impressive career, Noah has amassed a wealth of experience in designing innovative partnerships and corporate transactions between a broad range of biotechnology and pharmaceutical companies. In addition, he has been instrumental in building successful organizations, and we welcome him to our core management team and as strategic leadership for establishing Poxel in the US market.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK